Analyst Price Targets — NPCE
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| May 15, 2026 4:57 pm | — | H.C. Wainwright | $20.00 | $15.09 | TheFly | NeuroPace price target raised to $20 from $19 at H.C. Wainwright |
| January 27, 2026 11:04 am | — | H.C. Wainwright | $19.00 | $16.23 | TheFly | NeuroPace price target raised to $19 from $18 at H.C. Wainwright |
| December 16, 2025 12:49 pm | — | UBS | $22.00 | $15.93 | TheFly | NeuroPace price target raised to $22 from $18 at UBS |
| December 9, 2025 12:58 pm | Priya Sachdeva | UBS | $18.00 | $16.37 | StreetInsider | UBS Reiterates Buy Rating on NeuroPace Inc (NPCE) Post NAUTILUS Trial Results |
| November 5, 2025 11:20 am | Mike Kratky | Leerink Partners | $19.00 | $9.40 | StreetInsider | NeuroPace Inc (NPCE) PT Raised to $19 at Leerink Partners |
| November 5, 2025 11:04 am | Ross Osborn | Cantor Fitzgerald | $16.00 | $9.40 | StreetInsider | Cantor Fitzgerald Says NeuroPace Inc (NPCE) Remains a Top Pick |
| August 14, 2024 6:30 am | Vik Chopra | Wells Fargo | $15.00 | $7.28 | TheFly | NeuroPace price target lowered to $15 from $20 at Wells Fargo |
| May 23, 2024 8:44 am | Frank Takkinen | Lake Street | $20.00 | $7.99 | TheFly | NeuroPace post Q1 move 'overdone,' says Lake Street |
| March 14, 2024 5:08 am | Larry Biegelsen | Wells Fargo | $20.00 | $13.63 | StreetInsider | Wells Fargo Upgrades NeuroPace Inc (NPCE) to Overweight |
| November 10, 2023 2:34 pm | Ross Osborn | Cantor Fitzgerald | $11.00 | $7.85 | Benzinga | Epilepsy-Focused MedTech NeuroPace Has Attractive Entry Point, Competitive Position |
Latest News for NPCE
NPCE's RNS adoption, referral growth and AI innovation support expansion, while IGE timing and investments may pressure near-term profits.
The mean of analysts' price targets for NeuroPace (NPCE) points to a 27.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
NeuroPace (NPCE) reported earnings 30 days ago. What's next for the stock?
NPCE rides strong RNS adoption and AI tools nearing FDA review, with a mid-2026 IGE decision offering upside despite near-term losses.
NeuroPace wins FDA OK for ECoG Assistant, its first AI feature for epilepsy care, leveraging RNS EEG data to speed ECoG review and insights.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for NPCE.
U.S. House Trading
No House trades found for NPCE.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.